Pathophysiology—Prostate Cancer
作者： Philip J. Saylor , Matthew R. Smith
DOI: 10.1016/B978-0-12-415853-5.00061-3
关键词:
摘要: Androgen deprivation therapy (ADT) is the foundation of systemic for prostate cancer. Although it an effective cancer treatment in a variety clinical settings, causes accelerated loss bone mineral density (BMD) and associated with increased incidence fractures. National Comprehensive Cancer Network (NCCN) guidelines management advocate use World Health Organization (WHO) fracture risk assessment model (FRAX) among men receiving ADT Several classes agents have been shown to produce benefits need drug therapy. Bisphosphonates improve BMD ADT. A large phase III placebo-controlled fracture-prevention trial showed that denosumab improved both The potential treatment-related adverse effects these highlights rational selection candidates.
elsevier.com
sci-hub.se 参考文章(91)
Beatrice J. Edwards, John W. Hellstein, Peter L. Jacobsen, Steven Kaltman, Angelo Mariotti, Cesar A. Migliorati, Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy The Journal of the American Dental Association. ,vol. 139, pp. 1674- 1677 ,(2008) , 10.14219/JADA.ARCHIVE.2008.0110
More on reports of esophageal cancer with oral bisphosphonate use. The New England Journal of Medicine. ,vol. 360, pp. 1789- 1790 ,(2009) , 10.1056/NEJMC096026
Young-Yun Kong, Hiroki Yoshida, Ildiko Sarosi, Hong-Lin Tan, Emma Timms, Casey Capparelli, Sean Morony, Antonio J. Oliveira-dos-Santos, Gwyneth Van, Annick Itie, Wilson Khoo, Andrew Wakeham, Colin R. Dunstan, David L. Lacey, Tak W. Mak, William J. Boyle, Josef M. Penninger, OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis Nature. ,vol. 397, pp. 315- 323 ,(1999) , 10.1038/16852
Dirk M. Anderson, Eugene Maraskovsky, William L. Billingsley, William C. Dougall, Mark E. Tometsko, Eileen R. Roux, Mark C. Teepe, Robert F. DuBose, David Cosman, Laurent Galibert, A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function Nature. ,vol. 390, pp. 175- 179 ,(1997) , 10.1038/36593
Paolo Vescovi, Elisabetta Merigo, Marco Meleti, Maddalena Manfredi, Rebecca Guidotti, Samir Nammour, Bisphosphonates-related osteonecrosis of the jaws: a concise review of the literature and a report of a single-centre experience with 151 patients. Journal of Oral Pathology & Medicine. ,vol. 41, pp. 214- 221 ,(2012) , 10.1111/J.1600-0714.2011.01091.X
B. Gullberg, O. Johnell, J.A. Kanis, World-wide Projections for Hip Fracture Osteoporosis International. ,vol. 7, pp. 407- 413 ,(1997) , 10.1007/PL00004148
Gail A. Greendale, Sharon Edelstein, Elizabeth Barrett-Connor, Endogenous Sex Steroids and Bone Mineral Density in Older Women and Men: The Rancho Bernardo Study Journal of Bone and Mineral Research. ,vol. 12, pp. 1833- 1843 ,(1997) , 10.1359/JBMR.1997.12.11.1833
C. De Laet, J. A. Kanis, A. Odén, H. Johanson, O. Johnell, P. Delmas, J. A. Eisman, H. Kroger, S. Fujiwara, P. Garnero, E. V. McCloskey, D. Mellstrom, L. J. Melton, P. J. Meunier, H. A. P. Pols, J. Reeve, A. Silman, A. Tenenhouse, Body mass index as a predictor of fracture risk: A meta-analysis Osteoporosis International. ,vol. 16, pp. 1330- 1338 ,(2005) , 10.1007/S00198-005-1863-Y
J. E. Fisher, M. J. Rogers, J. M. Halasy, S. P. Luckman, D. E. Hughes, P. J. Masarachia, G. Wesolowski, R. G. G. Russell, G. A. Rodan, A. A. Reszka, Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro Proceedings of the National Academy of Sciences of the United States of America. ,vol. 96, pp. 133- 138 ,(1999) , 10.1073/PNAS.96.1.133
Matthew R. Smith, Mary Anne Fallon, Hang Lee, Joel S. Finkelstein, Raloxifene to Prevent Gonadotropin-Releasing Hormone Agonist-Induced Bone Loss in Men with Prostate Cancer: A Randomized Controlled Trial The Journal of Clinical Endocrinology and Metabolism. ,vol. 89, pp. 3841- 3846 ,(2004) , 10.1210/JC.2003-032058